Warning! GuruFocus detected
5 Severe warning signs
with INO.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Inovio Pharmaceuticals Inc
NAICS : 325414
SIC : 2836
ISIN : US45773H2013
Compare
Compare
Traded in other countries / regions
INO.USA0A43.UKGBM.GermanyINO.Mexico Index Membership
Russell 2000Russell 3000Russell 3000Russell 2000 IPO Date
1998-12-08Description
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 7.93 | |||||
| Equity-to-Asset | 0.61 | |||||
| Debt-to-Equity | 0.17 | |||||
| Debt-to-EBITDA | -0.11 | |||||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | -22.9 | |||||
| Beneish M-Score | -2.65 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -57.2 | |||||
| 3-Year EBITDA Growth Rate | 39.2 | |||||
| 3-Year EPS without NRI Growth Rate | 37.9 | |||||
| 3-Year FCF Growth Rate | 32.4 | |||||
| 3-Year Book Growth Rate | -55.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 28.96 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 594.57 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 35.56 | |||||
| 9-Day RSI | 41.67 | |||||
| 14-Day RSI | 43.31 | |||||
| 3-1 Month Momentum % | 21.74 | |||||
| 6-1 Month Momentum % | -65.43 | |||||
| 12-1 Month Momentum % | -79.6 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.77 | |||||
| Quick Ratio | 2.77 | |||||
| Cash Ratio | 2.66 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -25.8 | |||||
| Shareholder Yield % | -25.63 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -51559.17 | |||||
| Net Margin % | -49199.08 | |||||
| FCF Margin % | -47965.14 | |||||
| ROE % | -119.02 | |||||
| ROA % | -81.98 | |||||
| ROIC % | -333.09 | |||||
| 3-Year ROIIC % | -635.65 | |||||
| ROC (Joel Greenblatt) % | -807.6 | |||||
| ROCE % | -106.45 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 240.05 | |||||
| PB Ratio | 1.01 | |||||
| Price-to-Tangible-Book | 1.01 | |||||
| EV-to-EBIT | 0.1 | |||||
| EV-to-EBITDA | 0.11 | |||||
| EV-to-Revenue | -50.98 | |||||
| EV-to-Forward-Revenue | 0.45 | |||||
| EV-to-FCF | 0.11 | |||||
| Price-to-GF-Value | 1.15 | |||||
| Price-to-Median-PS-Value | 7.38 | |||||
| Price-to-Net-Current-Asset-Value | 1.31 | |||||
| Price-to-Net-Cash | 1.4 | |||||
| Earnings Yield (Greenblatt) % | 1000 | |||||
| FCF Yield % | -148.53 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:INO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Inovio Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.218 | ||
| EPS (TTM) ($) | -3.99 | ||
| Beta | 2.03 | ||
| 3-Year Sharpe Ratio | -0.69 | ||
| 3-Year Sortino Ratio | -0.94 | ||
| Volatility % | 103.52 | ||
| 14-Day RSI | 43.31 | ||
| 14-Day ATR ($) | 0.13656 | ||
| 20-Day SMA ($) | 1.9755 | ||
| 12-1 Month Momentum % | -79.6 | ||
| 52-Week Range ($) | 1.74 - 14.748 | ||
| Shares Outstanding (Mil) | 36.67 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Inovio Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Inovio Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Inovio Pharmaceuticals Inc Frequently Asked Questions
What is Inovio Pharmaceuticals Inc(INO)'s stock price today?
The current price of INO is $1.92. The 52 week high of INO is $14.75 and 52 week low is $1.74.
When is next earnings date of Inovio Pharmaceuticals Inc(INO)?
The next earnings date of Inovio Pharmaceuticals Inc(INO) is 2025-05-13 Est..
Does Inovio Pharmaceuticals Inc(INO) pay dividends? If so, how much?
Inovio Pharmaceuticals Inc(INO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers